| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
38,650,000 |
| Market
Cap: |
252.00(M) |
| Last
Volume: |
288,521 |
Avg
Vol: |
354,500 |
| 52
Week Range: |
$5.27 - $11.16 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 6.2 |
| Insider 6 Months : 6.2 |
| Insider 3/6 Months : 12.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AngioDynamics designs, manufactures and sells a range of medical, surgical and diagnostic devices used by healthcare providers. Co.'s product offerings fall within three Global Business Units: Endovascular Therapies, Oncology/Surgery and Vascular Access. Co.'s technology products including auryon, the thrombectomy platform (which includes AngioVac, AlphaVac and thrombolytics) and nanoknife. Co.'s Peripheral Products include angiographic products and accessories, drainage products, and micro access kits. Co. provides a variety of dialysis catheters, including: BioFlo DuraMax, which is a dialysis catheter with Endexo Technology; and DuraMax, which is a stepped-tip catheter.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
10,000 |
10,000 |
21,083 |
| Total Buy Value |
$67,000 |
$67,000 |
$67,000 |
$231,967 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
9,633 |
| Total Sell Value |
$0 |
$0 |
$0 |
$172,197 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Burgstahler David F |
Director |
– • • |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
5,850 |
|
- |
|
| Bourne George W. Iv |
CTO and COO |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,055 |
18,018 |
|
- |
|
| Mcgill Stephen |
SVP, GM - International |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,382 |
21,890 |
|
- |
|
| Johnson Wesley |
Director |
– • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
13,850 |
|
- |
|
| Gold Jeffrey |
Director |
– • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
30,741 |
|
- |
|
| Frost Mark T |
EVP and CFO |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,519 |
27,519 |
|
- |
|
| Laporte Steve |
Director |
– • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
13,863 |
|
- |
|
| Donnelly Howard W |
Director |
– • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
15,850 |
|
- |
|
| Kapusta Matthew C |
SVP, Business Development |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,438 |
24,550 |
|
- |
|
| Richard Stark |
SVP, GM - Oncology |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,345 |
28,080 |
|
- |
|
| Gould Kevin J |
Director |
– • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
13,950 |
|
- |
|
| Greiner Charles R |
VP - Global Finance |
• – – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
5,139 |
26,315 |
|
- |
|
| Devivo Joseph |
President and Chief Executive |
• • – |
2013-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
18,388 |
76,551 |
|
- |
|
| Devivo Joseph |
President and Chief Executive |
• – – |
2013-08-03 |
4 |
D |
$12.04 |
$28,390 |
D/D |
(2,358) |
58,213 |
|
- |
|
| Greiner Charles R |
VP - Global Franchise |
• – – |
2013-08-03 |
4 |
D |
$12.04 |
$24,622 |
D/D |
(2,045) |
21,176 |
|
- |
|
| Kapusta Matthew C |
SVP, Business Development |
• – – |
2013-08-03 |
4 |
D |
$12.04 |
$6,381 |
D/D |
(530) |
19,112 |
|
- |
|
| Mcgill Stephen |
SVP, GM - International |
• – – |
2013-08-03 |
4 |
D |
$12.04 |
$34,651 |
D/D |
(2,878) |
16,508 |
|
- |
|
| Richard Stark |
SVP, GM - Oncology |
• – – |
2013-08-03 |
4 |
D |
$12.04 |
$28,390 |
D/D |
(2,358) |
22,735 |
|
- |
|
| Gould Kevin J |
Director |
– • – |
2013-07-22 |
4 |
B |
$12.00 |
$32,400 |
D/D |
2,700 |
10,950 |
2.39 |
- |
|
| Bourne George W. Iv |
CTO and COO |
• – – |
2013-05-21 |
4 |
D |
$10.96 |
$10,390 |
D/D |
(948) |
11,963 |
|
- |
|
| Greiner Charles R |
VP - Global Franchise |
• – – |
2013-05-09 |
4 |
S |
$10.38 |
$15,518 |
D/D |
(1,495) |
23,221 |
|
- |
|
| Gold Jeffrey |
Director |
– • – |
2013-03-25 |
4 |
OE |
$6.52 |
$16,356 |
D/D |
2,508 |
27,741 |
|
- |
|
| Bucci Vincent |
Director |
– • – |
2013-03-12 |
4 |
B |
$10.76 |
$484,600 |
I/I |
45,000 |
13,000 |
2.1 |
- |
|
| Bucci Vincent |
Director |
– • – |
2013-03-12 |
4 |
B |
$10.78 |
$431,200 |
D/D |
40,000 |
78,696 |
2.39 |
- |
|
| Meteny Dennis S |
Director |
– • – |
2013-03-12 |
4 |
B |
$10.82 |
$49,772 |
D/D |
4,600 |
21,950 |
2.39 |
- |
|
1050 Records found
|
|
Page 21 of 42 |
|
|
0.02 (0.31%) 
